The use of kits and reagents in the preparation of kits

A kit and technology for use, applied in a kit for diagnosing acute coronary syndrome, and the reagent in the field of kit preparation

Active Publication Date: 2021-01-15
PEOPLES HOSPITAL PEKING UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although there are some studies on plaque rupture markers, such as some cytokines, growth factors, enzymes, etc., these markers are still far from clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The use of kits and reagents in the preparation of kits
  • The use of kits and reagents in the preparation of kits
  • The use of kits and reagents in the preparation of kits

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1 Differential expression profile of miRNAs 1h after plaque rupture compared to before rupture

[0047] The baseline data of all selected patients are shown in Table 1. Plasma samples were collected from 10 patients before balloon expansion (that is, before plaque rupture) and 1 hour after balloon expansion (that is, after plaque rupture). After RNA was extracted, microarray detection was performed. A total of 24 miRNAs were differentially expressed 1 h after plaque rupture, 7 up-regulated miRNAs, and 14 down-regulated miRNAs, as shown in Table 2.

[0048] Table 1: Baseline data of the study population

[0049]

[0050] Table 2: Differential expression of miRNAs after plaque rupture

[0051]

[0052] The above are the miRNAs with differential expression fold (fold change)>2 times and false discovery rate (false discovery rate)<0.0001% between the two groups

Embodiment 2

[0053] Example 2 Verification of 24 differentially expressed miRNAs in the chip above:

[0054] In the other 10 patients, plasma samples were collected before balloon dilatation (that is, before plaque rupture) and 1 hour after balloon dilation (that is, after plaque rupture). After RNA was extracted, real-time PCR was used to detect The expression levels of 24 miRNAs were screened, and 8 miRNAs were still differentially expressed, including miR-155-5p, miR-212-3p, miR-483-5p, miR-1233-3p, miR-20b-5p, miR-122-5p, miR-451a, miR-486-5p, see figure 1 . In addition, because the expression abundance of miR-376a is very low, it is almost undetectable in the first three, so the follow-up verification was abandoned.

[0055] Since the collected specimens before and after balloon dilation contained contrast agents, in order to eliminate the influence of contrast agents on miRNA levels, the inventors collected plasma from 10 patients before and after contrast, and detected the above-m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention provides application of a reagent in the preparation of a kit; the kit is used for diagnosing acute coronary syndrome; the reagent is used for detecting at least one of miR-155-5p, miR-483-5p, and miR-451a. The inventor discovers through experiments that miR-155-5p, miR-483-5p or miR-451a has significant expression differences before and after plaque rapture, and has good diagnostic value in the early diagnosis for the rapture of coronary plaque; the kit prepared with the reagent for detecting at least one of miR-155-5p, miR-483-5p, and miR-451a is effectively applicable to the early diagnosis of the rupture of coronary plaque, and has the advantages of high sensitivity and high specificity.

Description

technical field [0001] The invention relates to the field of biology, in particular, the invention relates to a kit for diagnosing acute coronary syndrome and the use of the reagent in preparing the kit. Background technique [0002] Acute coronary syndrome mainly includes unstable angina, acute myocardial infarction and sudden cardiac death. The main pathological basis of acute coronary syndrome is the rupture of coronary plaque and secondary thrombosis. Early identification of patients with plaque rupture and timely administration of antithrombotic therapy have very important clinical significance for preventing and preventing malignant adverse cardiovascular events (such as acute myocardial infarction) in these patients. However, there are currently no good diagnostic tools or markers for identifying patients with coronary plaque rupture. For the clinically most common acute myocardial infarction patients, the diagnosis can only be made when there is an increase in card...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883C12N15/11
CPCC12Q1/6883C12Q2600/178
Inventor 陈红李素芳李忠佑宋俊贤仁晖
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap